Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
UnitedHealth Group Incorporated operates as a health care company in the United States and internationally. It operates through four segments: Optum Health, Optum Insight, Optum Rx; and UnitedHealthcare. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services with patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, public entities, life sciences companies and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease and drug therapy management. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; Medicaid plans, including Temporary Assistance to Needy Families; Children's Health Insurance Programs; Dual SNPs; Long-Term Services and Supports; Aged, Blind and Disabled; and other federal, state, and community health care programs. and health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. UnitedHealth Group Incorporated was founded in 1974 and is based in Eden Prairie, Minnesota.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $447.6B | $23.1B | $12.1B | $16.1B | 12.8% | 11.8% | -16.3% |
| 2024 | $400.3B | $28.1B | $14.4B | $20.7B | 15.5% | 7.7% | -35.6% |
| 2023 | $371.6B | $36.3B | $22.4B | $25.7B | 25.2% | 14.6% | 11.2% |
| 2022 | $324.2B | $31.8B | $20.1B | $23.4B | 25.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 324,162 | 371,622 | 400,278 | 447,567 |
| Operating Revenue | - | 324,162 | 371,622 | 400,278 | 447,567 |
| Cost Of Revenue | - | 244,545 | 280,664 | 310,879 | 364,650 |
| Gross Profit | - | 79,617 | 90,958 | 89,399 | 82,917 |
| Operating Expense | - | 51,182 | 58,600 | 57,112 | 63,953 |
| Total Expenses | - | 295,727 | 339,264 | 367,991 | 428,603 |
| Operating Income | - | 28,435 | 32,358 | 32,287 | 18,964 |
| Total Operating Income As Reported | - | 28,435 | 32,358 | 32,287 | 18,964 |
| EBITDA | - | 31,835 | 36,330 | 28,076 | 23,060 |
| Normalized EBITDA | - | 31,835 | 36,330 | 36,386 | 23,325 |
| EBIT | - | 28,435 | 32,358 | 23,977 | 18,699 |
| Interest Expense | - | 2,092 | 3,246 | 3,906 | 4,002 |
| Net Interest Income | - | -2,092 | -3,246 | -3,906 | -4,002 |
| Other Income Expense | - | 2,030 | 4,089 | -8,310 | -265 |
| Interest Expense Non Operating | - | 2,092 | 3,246 | 3,906 | 4,002 |
| Net Non Operating Interest Income Expense | - | -2,092 | -3,246 | -3,906 | -4,002 |
| Pretax Income | - | 26,343 | 29,112 | 20,071 | 14,697 |
| Tax Provision | - | 5,704 | 5,968 | 4,829 | 1,890 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | -2,002.71 | -34.18 |
| Net Income Continuous Operations | - | 20,639 | 23,144 | 15,242 | 12,807 |
| Net Income From Continuing And Discontinued Operation | - | 20,120 | 22,381 | 14,405 | 12,056 |
| Net Income From Continuing Operation Net Minority Interest | - | 20,120 | 22,381 | 14,405 | 12,056 |
| Net Income | - | 20,120 | 22,381 | 14,405 | 12,056 |
| Net Income Common Stockholders | - | 20,120 | 22,381 | 14,405 | 12,056 |
| Net Income Including Noncontrolling Interests | - | 20,639 | 23,144 | 15,242 | 12,807 |
| Normalized Income | - | 20,120 | 22,381 | 20,712.29 | 12,286.82 |
| Diluted NI Availto Com Stockholders | - | 20,120 | 22,381 | 14,405 | 12,056 |
| Basic Average Shares | - | 934 | 924 | 915 | 905.84 |
| Diluted Average Shares | - | 950 | 938 | 929 | 911 |
| Reconciled Depreciation | - | 3,400 | 3,972 | 4,099 | 4,361 |
| Reconciled Cost Of Revenue | - | 244,545 | 280,664 | 310,879 | 364,650 |
| Total Unusual Items | - | 0 | 0 | -8,310 | -265 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | -8,310 | -265 |
| Minority Interests | - | -519 | -763 | -837 | -751 |
| Special Income Charges | - | 0 | 0 | -8,310 | -265 |
| Gain On Sale Of Business | - | 0 | 0 | -8,310 | -265 |
| Gain On Sale Of Security | 2,324 | 2,030 | 4,089 | - | - |
| Depreciation Amortization Depletion Income Statement | - | 3,400 | 3,972 | 4,099 | 4,361 |
| Depreciation And Amortization In Income Statement | - | 3,400 | 3,972 | 4,099 | 4,361 |
| Other Operating Expenses | - | 47,782 | 54,628 | 53,013 | 59,592 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| UnitedHealth Group Incorporatedthis co. | UNH | $360.1B | 29.86↑ premium | 3.83 | 12.8% | 17.96 |
| Johnson & Johnson | JNJ | $549.3B | 20.49 | 6.74 | 32.9% | 14.07 |
| AbbVie Inc. | ABBV | $397.4B | 94.94 | - | -128.0% | 26.07 |
| Merck & Co., Inc. | MRK | $297.0B | 16.27 | 5.65 | 34.7% | 11.74 |
| Amgen Inc. | AMGN |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $186.5B |
| 24.19 |
| 21.54 |
| 89.1% |
| 13.73 |
| Thermo Fisher Scientific Inc. | TMO | $179.1B | 26.72 | 3.35 | 12.6% | 18.11 |
| Gilead Sciences, Inc. | GILD | $160.4B | 18.85 | 7.06 | 37.5% | 12.94 |
| Abbott Laboratories | ABT | $158.1B | 24.24 | 3.03 | 12.5% | 13.54 |
| Intuitive Surgical, Inc. | ISRG | $148.3B | 51.94 | 8.32 | 16.0% | 39.33 |
| Peer Median | - | 24.21 | 6.74 | 24.4% | 13.90 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Oct has averaged the highest return (+5.9%); Jan the lowest (-4.1%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.1%Negative MonthJan 2026: -13.08% | +2.2%Positive MonthFeb 2026: +2.21% | -7.7%Negative MonthMar 2026: -7.73% | +36.9%Positive MonthApr 2026: +36.92% | +2.7%Positive MonthMay 2026: +2.65% | +9.3%Positive MonthJun 2026: +9.29% | -0.3%Neutral MonthJul 2026: -0.30% | -6.2%*Negative MonthAug 2026: -6.22% | — | — | — | — |
| 2025 | +7.2%Positive MonthJan 2025: +7.24% | -12.4%Negative MonthFeb 2025: -12.45% | +10.3%Positive MonthMar 2025: +10.27% | -21.4%Negative MonthApr 2025: -21.44% | -26.6%Negative MonthMay 2025: -26.62% | +3.3%Positive MonthJun 2025: +3.33% | -20.0%Negative MonthJul 2025: -20.01% | +24.2%Positive MonthAug 2025: +24.17% | +11.4%Positive MonthSep 2025: +11.43% | -1.1%Neutral MonthOct 2025: -1.08% | -3.5%Negative MonthNov 2025: -3.45% | +0.1%Neutral MonthDec 2025: +0.10% |
| 2024 | -2.8%Negative MonthJan 2024: -2.80% | -3.5%Negative MonthFeb 2024: -3.54% | +0.2%Neutral MonthMar 2024: +0.22% | -2.2%Negative MonthApr 2024: -2.22% | +2.4%Positive MonthMay 2024: +2.41% | +2.8%Positive MonthJun 2024: +2.80% | +13.1%Positive MonthJul 2024: +13.14% | +2.4%Positive MonthAug 2024: +2.44% | -0.9%Neutral MonthSep 2024: -0.94% | -3.5%Negative MonthOct 2024: -3.45% | +8.1%Positive MonthNov 2024: +8.10% | -17.1%Negative MonthDec 2024: -17.10% |
| 2023 | -5.8%Negative MonthJan 2023: -5.85% | -4.7%Negative MonthFeb 2023: -4.66% | -0.7%Neutral MonthMar 2023: -0.70% | +4.1%Positive MonthApr 2023: +4.13% | -1.0%Neutral MonthMay 2023: -0.99% | -1.4%Neutral MonthJun 2023: -1.35% | +5.4%Positive MonthJul 2023: +5.35% | -5.9%Negative MonthAug 2023: -5.88% | +5.8%Positive MonthSep 2023: +5.79% | +6.2%Positive MonthOct 2023: +6.22% | +3.3%Positive MonthNov 2023: +3.25% | -4.8%Negative MonthDec 2023: -4.79% |
| 2022 | -5.9%Negative MonthJan 2022: -5.89% | +0.7%Neutral MonthFeb 2022: +0.70% | +7.2%Positive MonthMar 2022: +7.17% | -0.3%Neutral MonthApr 2022: -0.28% | -2.3%Negative MonthMay 2022: -2.31% | +3.4%Positive MonthJun 2022: +3.39% | +5.6%Positive MonthJul 2022: +5.59% | -4.2%Negative MonthAug 2022: -4.24% | -2.8%Negative MonthSep 2022: -2.75% | +9.9%Positive MonthOct 2022: +9.92% | -1.3%Neutral MonthNov 2022: -1.33% | -3.2%Negative MonthDec 2022: -3.21% |
| 2021 | — | — | — | — | +3.3%Positive MonthMay 2021: +3.29% | -2.8%Negative MonthJun 2021: -2.79% | +2.9%Positive MonthJul 2021: +2.94% | +1.0%Neutral MonthAug 2021: +0.98% | -6.1%Negative MonthSep 2021: -6.13% | +17.8%Positive MonthOct 2021: +17.85% | -3.5%Negative MonthNov 2021: -3.53% | +13.0%Positive MonthDec 2021: +13.04% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
